Genmab announced termination of clinical development for acasunlimab, a bispecific antibody previously co-developed with BioNTech until BioNTech withdrew last year. The Danish biotech said the decision follows strategic reassessment and interim Phase 3 findings that failed to support continued investment. Acasunlimab targeted solid-tumor indications with a bispecific format designed to engage immune effector functions. Genmab’s termination indicates the company will redirect R&D resources toward other pipeline candidates and technology platforms. The move highlights the fragility of co-development programs when a major partner departs; it also signals investor pressure on biotechs to focus capital on higher-probability assets. Genmab will provide data summaries and next-step guidance to shareholders as it winds down the program. Industry watchers expect the termination to prompt sharper scrutiny of bispecific portfolios across mid-cap developers and could accelerate M&A or out-licensing conversations for non-core assets.